In HIV patients on placebo, losing visceral fat didn't lead to lower liver enzymes, unlike those taking tesamorelin.

Even after accounting for other factors like sex and hepatitis, higher visceral fat was still linked to higher ALT levels in HIV patients with high liver enzymes.

Even after stopping tesamorelin and some fat coming back, the liver enzyme improvements stayed for a year in patients who initially lost visceral fat.

For HIV patients with belly fat and high liver enzymes, taking a placebo even if they lost visceral fat didn't help lower their liver enzyme levels, unlike those taking the actual drug.

When people with HIV and belly fat lost fat from a placebo pill, their liver enzymes didn't improve, but when they lost fat from tesamorelin, their liver enzymes did improve.

HIV patients with high liver enzymes who lost at least 8% visceral fat after taking tesamorelin saw their ALT drop by about 9 units on average, while those without fat loss had a slight increase, showing a clear benefit from fat reduction.